The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia

Annals of Oncology : Official Journal of the European Society for Medical Oncology
I HusA Dmoszyńska

Abstract

B-cell chronic lymphocytic leukaemia (B-CLL) is a disease with a highly variable clinical course; some patients never need treatment, while others require intensive treatment early after diagnosis. Recently, some new prognostic factors, such as IgVH mutational status, ZAP-70 and the expression of CD38 in leukaemic cells were introduced to identify attenuated versus progressive types of CLL bearing the potential to facilitate risk-adapted treatment strategies. To evaluate the clinical value of ZAP-70 and CD38 as predictors of disease progression we assessed the expression of these markers by the flow cytometry method in 156 B-CLL patients. Both ZAP-70 and CD38 expression were shown to predict the clinical course of the disease, while ZAP-70 expression appeared to be more predictive than CD38 expression and more relevant in defining the cases of B-CLL responsive or refractory to first line chemotherapy. A simultaneous evaluation of ZAP-70 and CD38 expression allowed distinguishing the patients groups with the most favourable prognosis as well as those with the worst. Taken together we recommend assessing both ZAP-70 and CD38 protein expression for the definition of prognostic subgroups in patients with B-CLL.

References

Jul 6, 2000·Current Opinion in Hematology·T J Kipps
Feb 14, 2002·British Journal of Haematology·Patrice ChevallierRichard Garand
Jul 11, 2002·Annals of Hematology·T Hamblin
May 2, 2003·The New England Journal of Medicine·Marta CrespoEmili Montserrat
Jan 17, 2004·Lancet·Jenny A OrchardDavid G Oscier

❮ Previous
Next ❯

Citations

Jul 31, 2012·Cancer Immunology, Immunotherapy : CII·Mercedes BorgeRomina Gamberale
Feb 1, 2007·Current Hematologic Malignancy Reports·Neil E Kay, Tait D Shanafelt
Nov 22, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Angélique BiancottoJ Philip McCoy
Dec 27, 2013·Indian Journal of Cancer·A GogiaR Kumar
Oct 26, 2011·Leukemia & Lymphoma·Pauline Y HuangRichard I Christopherson
Jan 5, 2010·Medicina clínica·José Angel HernándezJesús María Hernández
Jul 5, 2008·Blood Reviews·Femke Van BockstaeleJan Philippé
Oct 2, 2007·Cancer Treatment Reviews·Tadeusz Robak
Feb 28, 2009·Hematological Oncology·Nashwa Khayrat AbousamraEmad Azmy
Sep 24, 2009·Journal of Clinical Laboratory Analysis·Roger S RileyJonathan M Ben-Ezra
Apr 8, 2011·Cytometry. Part B, Clinical Cytometry·Heba A DegheidyGerald E Marti
May 2, 2008·Blood Reviews·Carol Moreno, Emili Montserrat
Jan 15, 2014·Leukemia Research·Agnieszka Bojarska-JunakJacek Roliński
Dec 13, 2016·Expert Review of Hematology·Michael T Tees, Ian W Flinn
Feb 14, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan O'BrienKanti R Rai
Aug 15, 2006·Cytometry. Part B, Clinical Cytometry·Adrian Wiestner
Aug 15, 2006·Cytometry. Part B, Clinical Cytometry·Francesc BoschEmili Montserrat
Aug 15, 2006·Cytometry. Part B, Clinical Cytometry·Laura Z Rassenti, Thomas J Kipps
Aug 15, 2006·Cytometry. Part B, Clinical Cytometry·Keith E ShultsGregory T Stelzer
Aug 15, 2006·Cytometry. Part B, Clinical Cytometry·Bruce H Davis, Michael Schwartz
May 31, 2007·American Journal of Hematology·Giovanni D'ArenaLuca Laurenti
Nov 25, 2006·Hematology·Emili Montserrat
May 28, 2019·BMC Research Notes·Ameen Abdulaziz BasabaeenIbrahim Khider Ibrahim
Feb 8, 2007·Cytometry. Part B, Clinical Cytometry·Gerald MartiCharles L Goolsby
Aug 1, 2020·The Cochrane Database of Systematic Reviews·Nina KreuzbergerNicole Skoetz
Sep 17, 2009·Acta Medica (Hradec Králové)·Vladimíra VroblováJan Krejsek
Sep 18, 2020·Cancers·Michał ZarobkiewiczAgnieszka Bojarska-Junak
Sep 10, 2018·Archivum Immunologiae Et Therapiae Experimentalis·Agata SzymańskaIwona Hus
Jul 3, 2021·Cancers·Justyna WośAgnieszka Bojarska-Junak

❮ Previous
Next ❯